University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19.  Major medical centers in Germany and Italy are considering joining the study.  The study will evaluate the effect of Leukine® on lung function and patient outcomes.
Pharmaceutical company Janssen Pharmaceutica and gin distillery Filliers Distillery are making disinfectant hand gel from Sunday. They will distribute it among the Belgian hospitals.
At the University of Antwerp, twelve product developers are working day and night to develop oral masks. "Together with industrial partners, we try to set up an emergency production for protective equipment for health workers during this corona crisis".
Developing a vaccine takes a long time and occurs in different phases. A virus spreads quickly and unpredictably. Therefore, the outcome is a gamble for anyone in the race for the corona vaccine.
The Bill & Melinda Gates Foundation is to provide samples of 15,000 therapeutic molecules to the Gasthuisberg hospital at the University of Leuven, to aid research into therapies to combat the coronavirus COVID-19, De Standaard reports.
Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique antibody that is capable of binding the virus that causes COVID-19 (SARS-CoV-2). The antibody was developed in collaboration with two research groups in the US. The team has now established that the antibody can neutralize a lab variant of the virus, an important step forward in the development of a potential antiviral drug against the new coronavirus. This progress was made possible thanks to the intensive efforts of various teams in the VIB-UGent Center for Medical Biotechnology.
Inari Agriculture has been awarded the 2020 Newcomer of the Year Trophy by Flanders Investment & Trade (FIT). Inari (US) opened its first foreign R&D branch in Ghent’s biotech valley just over a year ago. Since then, the Belgian team has been hard at work developing plants that can address both growing global food requirements and climate change. They’re approaching the challenge with both the latest genetic techniques and with a fresh perspective on how a business should be run.
The biotech Bioxodes is using a molecule derived from tick saliva to stop blood clots. The Walloon company is focused on preventing thrombosis during procedures involving medical devices. The current gold-standard anticoagulant can cause unwanted bleeding and side effects; could a molecule derived from ticks really be safer?
Researchers have developed a new antibacterial strategy that weakens bacteria by preventing them from cooperating. The method involves attacking the protective biofilm produced by the whole bacterial colony, rather than the individual bacteria themselves. Because this results in non-resistant bacteria outcompeting their antibiotic resistant neighbors, the strategy does not promote the development of further resistance.
To improve sonar navigation systems used by self-driving robots, researchers from Belgium, The Netherlands and Germany have turned to nature for an ingenious solution. By studying the relationship between bats and flowers, scientists found that the plants were reflecting a specific sonar signal to guide the bats. They used this concept to create artificial sonar signposts.
Researchers studying a rare disease have identified a new gene responsible for human immune system regulation. An international collaboration combined information from both mouse models and a single human patient in an effort to find the underlying genetic cause of hemophagocytic syndrome. This discovery could potentially inspire a treatment for the deadly disease and provides new insights into the immune system.
Novosanis have been able to achieve great success with their clever yet simple urine sampling solution Colli-Pee®, largely thanks to their multidisciplinary approach to product development. We spoke with Novosanis CEO Vanessa Vankerckhoven about the company’s interesting origin story.
When patients take HIV medication, a small amount of the virus nonetheless stays hidden in the body, preventing a cure. This hiding place has finally been uncovered in a groundbreaking study led by UZ Gent researchers. With this ‘viral reservoir’ identified, researchers may finally be able to develop a cure for this devastating disease.
Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science for health event in September the visionary Christian Homsy, former Celyad CEO, will be presenting one of the keynote talks. In this BioVox interview, we asked him to share his thoughts on the challenges faced by a company that’s pushing boundaries in the oncology space.
Food waste is a major global issue exacerbated by premature fruit spoilage. A US company, StixFresh, is working together with VIB-KU Leuven Prof Patrick Van Dijck to develop a solution to the problem. The company has created stickers coated in a plant-based antimicrobial formula that protects fruit from fungal infections, extending their shelf life by several weeks.